Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

EUCAST reference testing of rezafungin susceptibility: impact of choice of plastic plates.

Arendrup MC, Jørgensen KM, Hare RK, Cuenca-Estrella M, Zaragoza O.

Antimicrob Agents Chemother. 2019 Jul 8. pii: AAC.00659-19. doi: 10.1128/AAC.00659-19. [Epub ahead of print]

PMID:
31285230
2.

An introduction to current standards of CARE in invasive fungal disease.

Richardson MD, Cuenca-Estrella M, Maertens J.

J Antimicrob Chemother. 2019 Mar 1;74(Supplement_2):ii2. doi: 10.1093/jac/dkz036.

PMID:
31222309
3.

Defining standards of CARE for invasive fungal diseases in the ICU.

Cuenca-Estrella M, Kett DH, Wauters J.

J Antimicrob Chemother. 2019 Mar 1;74(Supplement_2):ii9-ii15. doi: 10.1093/jac/dkz038.

PMID:
31222308
4.

ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.

Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, Garnacho-Montero J, Kanj SS, Machado FR, Montravers P, Sakr Y, Sanguinetti M, Timsit JF, Bassetti M.

Intensive Care Med. 2019 Jun;45(6):789-805. doi: 10.1007/s00134-019-05599-w. Epub 2019 Mar 25.

PMID:
30911804
5.

In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies.

Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A.

J Antimicrob Chemother. 2019 Jun 1;74(6):1586-1590. doi: 10.1093/jac/dkz078.

PMID:
30891600
6.

In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies.

Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A.

J Antimicrob Chemother. 2019 Feb 6. doi: 10.1093/jac/dkz022. [Epub ahead of print]

PMID:
30753499
7.

Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project.

Bassetti M, Scudeller L, Giacobbe DR, Lamoth F, Righi E, Zuccaro V, Grecchi C, Rebuffi C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S, Azoulay E, Blot SI, Cornely OA, Lass-Flörl C, Koehler P, Cuenca-Estrella M, de Lange DW, De Rosa FG, De Waele JJ, Dimopoulos G, Garnacho-Montero J, Hoenigl M, Kanj SS, Maertens J, Martin-Loeches I, Muñoz P, Kullberg BJ, Agvald-Ohman C, Poulakou G, Rello J, Sanguinetti M, Taccone FS, Timsit JF, Torres A, Vazquez JA, Calandra T; from the Study Group for Infections in Critically Ill Patients (ESGCIP) and the Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID); European Society of Intensive Care Medicine (ESICM); European Confederation of Medical Mycology (ECMM); Mycoses Study Group Education and Research Consortium (MSGERC).

Mycoses. 2019 Apr;62(4):310-319. doi: 10.1111/myc.12869. Epub 2019 Jan 22.

PMID:
30426598
8.

Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI.

Garcia-Vidal C, Alastruey-Izquierdo A, Aguilar-Guisado M, Carratalà J, Castro C, Fernández-Ruiz M, Aguado JM, Fernández JM, Fortún J, Garnacho-Montero J, Gavaldà J, Gudiol C, Guinea J, Gómez-López A, Muñoz P, Pemán J, Rovira M, Ruiz-Camps I, Cuenca-Estrella M.

Enferm Infecc Microbiol Clin. 2018 Jun 27. pii: S0213-005X(18)30200-3. doi: 10.1016/j.eimc.2018.03.018. [Epub ahead of print] English, Spanish.

PMID:
29960829
9.

Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study).

Alastruey-Izquierdo A, Alcazar-Fuoli L, Rivero-Menéndez O, Ayats J, Castro C, García-Rodríguez J, Goterris-Bonet L, Ibáñez-Martínez E, Linares-Sicilia MJ, Martin-Gomez MT, Martín-Mazuelos E, Pelaez T, Peman J, Rezusta A, Rojo S, Tejero R, Anza DV, Viñuelas J, Zapico MS, Cuenca-Estrella M; the FILPOP2 Project from GEMICOMED (SEIMC) and REIPI.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00358-18. doi: 10.1128/AAC.00358-18. Print 2018 Sep.

10.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

11.

Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method.

Arendrup MC, Meletiadis J, Zaragoza O, Jørgensen KM, Marcos-Zambrano LJ, Kanioura L, Cuenca-Estrella M, Mouton JW, Guinea J.

Clin Microbiol Infect. 2018 Nov;24(11):1200-1204. doi: 10.1016/j.cmi.2018.02.021. Epub 2018 Mar 2.

PMID:
29505881
12.

Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America.

Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, López-Vélez R, Cuenca-Estrella M, Torre-Cisneros J, Petersen E, Camargo LFA, Wright AJ, Beeching NJ, Vilela EG, Santoro-Lopes G, Len O, Stucchi RSB, Manuel O, Faria LC, Leblebicioglu H, Huprikar S, Molina I, Mourão PHO, Kotton CN, Aguado JM; working group on Endemic Disease and Travel Medicine in Solid-Organ Transplantation.

Transplantation. 2018 Feb;102(2):193-208. doi: 10.1097/TP.0000000000002027. Review. Erratum in: Transplantation. 2019 Jan;103(1):e38. Rabagliatti, Ricardo [corrected to Rabagliati, Ricardo].

PMID:
29381647
13.

Endemic Fungal Infection Recommendations for Solid-Organ Transplant Recipients and Donors.

Abdala E, Miller R, Pasqualotto AC, Muñoz P, Colombo AL, Cuenca-Estrella M.

Transplantation. 2018 Feb;102(2S Suppl 2):S52-S59. doi: 10.1097/TP.0000000000002020. Review. No abstract available.

PMID:
29381578
14.

Development and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus.

Bernal-Martínez L, Gil H, Rivero-Menéndez O, Gago S, Cuenca-Estrella M, Mellado E, Alastruey-Izquierdo A.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01083-17. doi: 10.1128/AAC.01083-17. Print 2017 Dec.

15.

Epidemiology and prognosis of candidaemia in elderly patients.

Ramos-Martínez A, Vicente-López N, Sánchez-Romero I, Padilla B, Merino-Amador P, Garnacho-Montero J, Ruiz-Camps I, Montejo M, Salavert M, Mensa J, Cuenca-Estrella M; Members of the CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI.

Mycoses. 2017 Dec;60(12):808-817. doi: 10.1111/myc.12677. Epub 2017 Aug 23.

PMID:
28836309
16.

Performance of a Quantitative PCR-Based Assay and Beta-d-Glucan Detection for Diagnosis of Invasive Candidiasis in Very-Low-Birth-Weight Preterm Neonatal Patients (CANDINEO Study).

Ramos JT, Villar S, Bouza E, Bergon-Sendin E, Perez Rivilla A, Collados CT, Andreu M, Reyes CS, Campos-Herrero MI, de Heredia JL, Herrera MCL, Alonso PA, Pallás-Alonso CR, Cuenca-Estrella M; CANDINEO Study Group.

J Clin Microbiol. 2017 Sep;55(9):2752-2764. doi: 10.1128/JCM.00496-17. Epub 2017 Jun 28.

17.

Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.

Marcos-Zambrano LJ, Puig-Asensio M, Pérez-García F, Escribano P, Sánchez-Carrillo C, Zaragoza O, Padilla B, Cuenca-Estrella M, Almirante B, Martín-Gómez MT, Muñoz P, Bouza E, Guinea J.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00099-17. doi: 10.1128/AAC.00099-17. Print 2017 Jul.

18.

Evaluation of MALDI-TOF-MS for the Identification of Yeast Isolates Causing Bloodstream Infection.

Turhan O, Ozhak-Baysan B, Zaragoza O, Er H, Sarıtas ZE, Ongut G, Ogunc D, Colak D, Cuenca-Estrella M.

Clin Lab. 2017 Apr 1;63(4):699-703. doi: 10.7754/Clin.Lab.2016.161101.

PMID:
28397475
19.

Changes in the epidemiological landscape of invasive mould infections and disease.

Lass-Flörl C, Cuenca-Estrella M.

J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i5-i11. doi: 10.1093/jac/dkx028.

PMID:
28355462
20.

Triazole Resistance in Aspergillus Species: An Emerging Problem.

Garcia-Rubio R, Cuenca-Estrella M, Mellado E.

Drugs. 2017 Apr;77(6):599-613. doi: 10.1007/s40265-017-0714-4. Review.

PMID:
28236169
21.

Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance.

Fernández-Ruiz M, Guinea J, Lora-Pablos D, Zaragoza Ó, Puig-Asensio M, Almirante B, Cuenca-Estrella M, Aguado JM; CANDIPOP Project; GEIH-GEMICOMED (SEIMC) and REIPI.

Clin Microbiol Infect. 2017 Sep;23(9):672.e1-672.e11. doi: 10.1016/j.cmi.2017.01.014. Epub 2017 Jan 29.

22.

Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study.

Duarte RF, Sánchez-Ortega I, Arnan M, Patiño B, Ayats J, Sureda A, Cuenca-Estrella M.

Bone Marrow Transplant. 2017 Feb;52(2):326-329. doi: 10.1038/bmt.2016.279. Epub 2016 Oct 31. No abstract available.

PMID:
27797367
23.

Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia.

Rueda C, Puig-Asensio M, Guinea J, Almirante B, Cuenca-Estrella M, Zaragoza O; CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI.

Clin Microbiol Infect. 2017 Jan;23(1):49.e1-49.e8. doi: 10.1016/j.cmi.2016.09.016. Epub 2016 Sep 24.

24.

Common Genetic Polymorphisms within NFκB-Related Genes and the Risk of Developing Invasive Aspergillosis.

Lupiañez CB, Villaescusa MT, Carvalho A, Springer J, Lackner M, Sánchez-Maldonado JM, Canet LM, Cunha C, Segura-Catena J, Alcazar-Fuoli L, Solano C, Fianchi L, Pagano L, Potenza L, Aguado JM, Luppi M, Cuenca-Estrella M, Lass-Flörl C, Einsele H, Vázquez L; PCRAGA Study Group, Ríos-Tamayo R, Loeffler J, Jurado M, Sainz J.

Front Microbiol. 2016 Aug 12;7:1243. doi: 10.3389/fmicb.2016.01243. eCollection 2016.

25.

Fungemia due to rare opportunistic yeasts: data from a population-based surveillance in Spain.

Fernández-Ruiz M, Guinea J, Puig-Asensio M, Zaragoza Ó, Almirante B, Cuenca-Estrella M, Aguado JM; CANDIPOP Project; GEIH-GEMICOMED (SEIMC) and REIPI.

Med Mycol. 2017 Feb 1;55(2):125-136. doi: 10.1093/mmy/myw055. Epub 2016 Aug 4.

PMID:
27495321
26.

Triazole Resistance in Aspergillus spp.: A Worldwide Problem?

Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, Cuenca-Estrella M.

J Fungi (Basel). 2016 Jul 4;2(3). pii: E21. doi: 10.3390/jof2030021. Review.

27.

Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort.

López-Cortés LE, Almirante B, Cuenca-Estrella M, Garnacho-Montero J, Padilla B, Puig-Asensio M, Ruiz-Camps I, Rodríguez-Baño J; members of the CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI.

Clin Microbiol Infect. 2016 Aug;22(8):733.e1-8. doi: 10.1016/j.cmi.2016.05.008. Epub 2016 May 14.

28.

Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.

Puig-Asensio M, Fernández-Ruiz M, Aguado JM, Merino P, Lora-Pablos D, Guinea J, Martín-Dávila P, Cuenca-Estrella M, Almirante B.

Antimicrob Agents Chemother. 2016 May 23;60(6):3291-300. doi: 10.1128/AAC.00195-16. Print 2016 Jun.

29.

EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents.

Arendrup MC, Meletiadis J, Mouton JW, Guinea J, Cuenca-Estrella M, Lagrou K, Howard SJ; Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST).

Clin Microbiol Infect. 2016 Jun;22(6):571.e1-4. doi: 10.1016/j.cmi.2016.01.017. Epub 2016 Feb 3.

30.

Diagnostics and susceptibility testing in Aspergillus.

Bernal-Martínez L, Alastruey-Izquierdo A, Cuenca-Estrella M.

Future Microbiol. 2016;11(2):315-28. doi: 10.2217/fmb.15.140. Epub 2016 Feb 5. Review.

PMID:
26848512
31.

Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is Aspergillus?

Morton CO, White PL, Barnes RA, Klingspor L, Cuenca-Estrella M, Lagrou K, Bretagne S, Melchers W, Mengoli C, Caliendo AM, Cogliati M, Debets-Ossenkopp Y, Gorton R, Hagen F, Halliday C, Hamal P, Harvey-Wood K, Jaton K, Johnson G, Kidd S, Lengerova M, Lass-Florl C, Linton C, Millon L, Morrissey CO, Paholcsek M, Talento AF, Ruhnke M, Willinger B, Donnelly JP, Loeffler J; EAPCRI.

Med Mycol. 2017 Jun 1;55(4):402-413. doi: 10.1093/mmy/myw093.

PMID:
28339744
32.

Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium.

Lupiañez CB, Canet LM, Carvalho A, Alcazar-Fuoli L, Springer J, Lackner M, Segura-Catena J, Comino A, Olmedo C, Ríos R, Fernández-Montoya A, Cuenca-Estrella M, Solano C, López-Nevot MÁ, Cunha C, Oliveira-Coelho A, Villaescusa T, Fianchi L, Aguado JM, Pagano L, López-Fernández E, Potenza L, Luppi M, Lass-Flörl C, Loeffler J, Einsele H, Vazquez L; PCRAGA Study Group, Jurado M, Sainz J.

Infect Immun. 2015 Dec 14;84(3):643-57. doi: 10.1128/IAI.01359-15.

33.

In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.

Arendrup MC, Jensen RH, Cuenca-Estrella M.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):532-6. doi: 10.1128/AAC.02336-15. Print 2016 Jan.

34.

Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative.

White PL, Barnes RA, Springer J, Klingspor L, Cuenca-Estrella M, Morton CO, Lagrou K, Bretagne S, Melchers WJ, Mengoli C, Donnelly JP, Heinz WJ, Loeffler J; EAPCRI.

J Clin Microbiol. 2015 Sep;53(9):2832-7. doi: 10.1128/JCM.00905-15. Epub 2015 Jun 17.

35.

Analytical Comparison of In Vitro-Spiked Human Serum and Plasma for PCR-Based Detection of Aspergillus fumigatus DNA: a Study by the European Aspergillus PCR Initiative.

Loeffler J, Mengoli C, Springer J, Bretagne S, Cuenca-Estrella M, Klingspor L, Lagrou K, Melchers WJ, Morton CO, Barnes RA, Donnelly JP, White PL; European Aspergillus PCR Initiative.

J Clin Microbiol. 2015 Sep;53(9):2838-45. doi: 10.1128/JCM.00906-15. Epub 2015 Jun 17.

36.

Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance.

Fernández-Ruiz M, Puig-Asensio M, Guinea J, Almirante B, Padilla B, Almela M, Díaz-Martín A, Rodríguez-Baño J, Cuenca-Estrella M, Aguado JM; CANDIPOP Project; GEIH-GEMICOMED (SEIMC); REIPI.

J Infect. 2015 Sep;71(3):385-94. doi: 10.1016/j.jinf.2015.05.009. Epub 2015 May 30.

PMID:
26033696
37.

Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain.

Puig-Asensio M, Ruiz-Camps I, Fernández-Ruiz M, Aguado JM, Muñoz P, Valerio M, Delgado-Iribarren A, Merino P, Bereciartua E, Fortún J, Cuenca-Estrella M, Almirante B; CANDIPOP Project,; GEIH-GEMICOMED SEIMC; REIPI.

Clin Microbiol Infect. 2015 May;21(5):491.e1-10. doi: 10.1016/j.cmi.2014.12.027. Epub 2015 Jan 14.

38.

Burden of serious fungal infections in Spain.

Rodriguez-Tudela JL, Alastruey-Izquierdo A, Gago S, Cuenca-Estrella M, León C, Miro JM, Nuñez Boluda A, Ruiz Camps I, Sole A, Denning DW; University of Manchester in association with the LIFE program.

Clin Microbiol Infect. 2015 Feb;21(2):183-9. doi: 10.1016/j.cmi.2014.07.013. Epub 2014 Oct 29.

39.

Reply to Lewis et al.

Duarte RF, Sánchez-Ortega I, Cuenca-Estrella M.

Clin Infect Dis. 2015 Apr 15;60(8):1285. doi: 10.1093/cid/civ036. Epub 2015 Jan 26. No abstract available.

PMID:
25628382
40.

Erratum to: Antifungal susceptibility profile of cryptic species of Aspergillus.

Alastruey-Izquierdo A, Alcazar-Fuoli L, Cuenca-Estrella M.

Mycopathologia. 2015 Apr;179(3-4):333-4. doi: 10.1007/s11046-014-9842-5. No abstract available.

PMID:
25487976
41.

Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial.

Aguado JM, Vázquez L, Fernández-Ruiz M, Villaescusa T, Ruiz-Camps I, Barba P, Silva JT, Batlle M, Solano C, Gallardo D, Heras I, Polo M, Varela R, Vallejo C, Olave T, López-Jiménez J, Rovira M, Parody R, Cuenca-Estrella M; PCRAGA Study Group; Spanish Stem Cell Transplantation Group; Study Group of Medical Mycology of the Spanish Society of Clinical Microbiology and Infectious Diseases; Spanish Network for Research in Infectious Diseases.

Clin Infect Dis. 2015 Feb 1;60(3):405-14. doi: 10.1093/cid/ciu833. Epub 2014 Oct 21.

PMID:
25336623
42.

Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis.

Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B, Fernández de Sevilla A, Gudiol C, Ayats J, Cuenca-Estrella M.

Clin Infect Dis. 2014 Dec 15;59(12):1696-702. doi: 10.1093/cid/ciu673. Epub 2014 Aug 27.

PMID:
25165088
43.

The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.

Mesa-Arango AC, Trevijano-Contador N, Román E, Sánchez-Fresneda R, Casas C, Herrero E, Argüelles JC, Pla J, Cuenca-Estrella M, Zaragoza O.

Antimicrob Agents Chemother. 2014 Nov;58(11):6627-38. doi: 10.1128/AAC.03570-14. Epub 2014 Aug 25.

44.

EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.

Arendrup MC, Howard S, Lass-Flörl C, Mouton JW, Meletiadis J, Cuenca-Estrella M.

Antimicrob Agents Chemother. 2014 Nov;58(11):6432-6. doi: 10.1128/AAC.03779-14. Epub 2014 Aug 18.

45.

Genetic relatedness versus biological compatibility between Aspergillus fumigatus and related species.

Sugui JA, Peterson SW, Figat A, Hansen B, Samson RA, Mellado E, Cuenca-Estrella M, Kwon-Chung KJ.

J Clin Microbiol. 2014 Oct;52(10):3707-21. doi: 10.1128/JCM.01704-14. Epub 2014 Aug 6.

46.

Antifungal susceptibility profile of cryptic species of Aspergillus.

Alastruey-Izquierdo A, Alcazar-Fuoli L, Cuenca-Estrella M.

Mycopathologia. 2014 Dec;178(5-6):427-33. doi: 10.1007/s11046-014-9775-z. Epub 2014 Jun 28. Review. Erratum in: Mycopathologia. 2015 Apr;179(3-4):333-4.

PMID:
24972670
47.

Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients.

Fortún J, Meije Y, Buitrago MJ, Gago S, Bernal-Martinez L, Pemán J, Pérez M, Gómez-G Pedrosa E, Madrid N, Pintado V, Martín-Dávila P, Cobo J, Fresco G, Moreno S, Cuenca-Estrella M.

J Antimicrob Chemother. 2014 Nov;69(11):3134-41. doi: 10.1093/jac/dku225. Epub 2014 Jun 25.

PMID:
24970743
48.

Ribosomic DNA intergenic spacer 1 region is useful when identifying Candida parapsilosis spp. complex based on high-resolution melting analysis.

Gago S, Alastruey-Izquierdo A, Marconi M, Buitrago MJ, Kerhornou A, Kersey PJ, Mellado E, Cuenca-Estrella M, Rodríguez-Tudela JL, Cuesta I.

Med Mycol. 2014 Jul;52(5):472-81. doi: 10.1093/mmy/myu009. Epub 2014 May 20.

PMID:
24847037
49.

Invasive fungal infections in solid organ transplant recipients.

Gavaldà J, Meije Y, Fortún J, Roilides E, Saliba F, Lortholary O, Muñoz P, Grossi P, Cuenca-Estrella M; ESCMID Study Group for Infections in Compromised Hosts.

Clin Microbiol Infect. 2014 Sep;20 Suppl 7:27-48. doi: 10.1111/1469-0691.12660. Review.

50.

A second look at Emmonsia infection can make the difference.

Pelegrín I, Alastruey-Izquierdo A, Ayats J, Cuenca-Estrella M, Cabellos C.

Transpl Infect Dis. 2014 Jun;16(3):519-20. doi: 10.1111/tid.12214. Epub 2014 May 5. No abstract available.

PMID:
24796631

Supplemental Content

Loading ...
Support Center